Accepted Manuscript

Development of [18F]FAMTO: A novel fluorine-18 labelled positron emission tomography (PET) radiotracer for imaging CYP11B1 and CYP11B2 enzymes in adrenal glands

Salvatore Bongarzone, Filippo Basagni, Teresa Sementa, Nisha Singh, Caleb Gakpetor, Vincent Faugeras, Jayanta Bordoloi, Antony D. Gee

PII: S0969-8051(18)30235-X
DOI: https://doi.org/10.1016/j.nucmedbio.2018.11.002
Reference: NMB 8044
To appear in: Nuclear Medicine and Biology

Received date: 25 July 2018
Revised date: 2 November 2018
Accepted date: 4 November 2018

Please cite this article as: Salvatore Bongarzone, Filippo Basagni, Teresa Sementa, Nisha Singh, Caleb Gakpetor, Vincent Faugeras, Jayanta Bordoloi, Antony D. Gee, Development of [18F]FAMTO: A novel fluorine-18 labelled positron emission tomography (PET) radiotracer for imaging CYP11B1 and CYP11B2 enzymes in adrenal glands. Nmb (2018), https://doi.org/10.1016/j.nucmedbio.2018.11.002

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Development of $[^{18}F]$FAMTO: a novel fluorine-18 labelled positron emission tomography (PET) radiotracer for imaging CYP11B1 and CYP11B2 enzymes in adrenal glands

Salvatore Bongarzone, Filippo Basagni, Teresa Sementa, Nisha Singh, Caleb Gakpetor, Vincent Faugeras, Jayanta Bordoloi, Antony D. Gee

1School of Imaging Sciences & Biomedical Engineering, 4th floor Lambeth Wing, St Thomas' Hospital, King's College London, London SE1 7EH, United Kingdom

2Department of Neuroimaging, Institute of Psychiatry, King's College London, London SE5 8AF, United Kingdom.

Corresponding Author

Antony D. Gee, School of Imaging Sciences and Biomedical Engineering, King's College London 4th Floor, Lambeth Wing St Thomas' Hospital, London SE1 7EH.

Tel +44 (0) 2071888363 Fax: +44 (0) 20 718 85442 E-mail: antony.gee@kcl.ac.uk

Abbreviated Title $[^{18}F]$FAMTO Imaging adrenal gland lesions

Keywords: Metomidate; Adrenal Glands; Fluorine-18 Radiochemistry; Primary aldosteronism; CYP11B2; Positron Emission Tomography
ABSTRACT

Introduction

Primary aldosteronism accounts for 6-15% of hypertension cases, the single biggest contributor to global morbidity and mortality. Whilst ~50% of these patients have unilateral aldosterone-producing adenomas, only a minority of these have curative surgery as the current diagnosis of unilateral disease is poor. Carbon-11 radiolabelled metomidate ([11C]MTO) is a positron emission tomography (PET) radiotracer able to selectively identify CYP11B1/2 expressing adrenocortical lesions of the adrenal gland. However, the use of [11C]MTO is limited to PET centres equipped with on-site cyclotrons due to its short half-life of 20.4 minutes. Radiolabelling a fluorometomidate derivative with fluorine-18 (radioactive half life 109.8 min) in the para-aromatic position ([18F]FAMTO) has the potential to overcome this disadvantage and allow it to be transported to non-cyclotron-based imaging centres.

Methods

Two strategies for the one-step radio-synthesis of [18F]FAMTO were developed. [18F]FAMTO was obtained via radiofluorination via use of sulfonium salt (1) and boronic ester (2) precursors. [18F]FAMTO was evaluated in vitro by autoradiography of pig adrenal tissues and in vivo by determining its biodistribution in rodents. Rat plasma and urine were analysed to determine [18F]FAMTO metabolites.

Results

[18F]FAMTO is obtained from sulfonium salt (1) and boronic ester (2) precursors in 7% and 32% non-isolated radiochemical yield (RCY), respectively. Formulated [18F]FAMTO was obtained with >99% radiochemical and enantiomeric purity with a synthesis time of 140 minutes from the
trapping of $[^{18}\text{F}]$fluoride ion on an anion-exchange resin (QMA cartridge). *In vitro* autoradiography of $[^{18}\text{F}]$FAMTO demonstrated exquisite specific binding in CYP11B-rich pig adrenal glands. *In vivo* $[^{18}\text{F}]$FAMTO rapidly accumulates in adrenal glands. Liver uptake was about 34% of that in the adrenals and all other organs were <12% of the adrenal uptake at 60 minutes post injection. Metabolite analysis showed 13% unchanged $[^{18}\text{F}]$FAMTO in blood at 10 minutes post administration and rapid urinary excretion. *In vitro* assays in human blood showed a free fraction of 37.5%.

**Conclusions**

$[^{18}\text{F}]$FAMTO, a new $^{18}\text{F}$-labelled analogue of metomidate, was successfully synthesised. *In vitro* and *in vivo* characterization demonstrated high selectivity towards aldosterone-producing enzymes (CYP11B1 and CYP11B2), supporting the potential of this radiotracer for human investigation.
1. Introduction

The most common secondary cause of hypertension is primary aldosteronism (PA), which is reported in approximately 6-15% of all hypertensive patients. By the year 2025, PA is expected to directly impact one in four people with hypertension globally [1-7]. PA is characterized by an excess secretion of aldosterone, steroid hormone with mineralocorticoid activity produced by the zona glomerulosa of the adrenal cortex where aldosterone synthase (CYP11B2) enzymes play an essential role in aldosterone production [3, 8, 9]. Aldosterone increases sodium reabsorption and potassium excretion in the renal distal tubules and collecting ducts of nephrons, influencing water retention and blood pressure [3].

Therefore, pathological conditions showing an overproduction of aldosterone frequently lead to hypertension and hypokalaemia resulting in detrimental effects to an individual’s cardiovascular system [1]. Over 90% of all PA patients have a sporadic form [10]. The two most common subtypes of sporadic PA are unilateral aldosterone-producing adenomas (UAPA, 40%) or bilateral adrenal hyperplasia (BAH, 60%) [5, 11]. Correctly differentiating between the unique features of UAPA and BAH is crucial in identifying an appropriate intervention. UAPA is curable through surgical removal of the diseased adrenal whilst BAH is treated pharmacologically with mineralocorticoid receptor antagonists (e.g. spironolactone) [12]. The most significant obstacle for decision makers is the need to distinguish UAPA from other causes of PA such as BAH or non-functioning adrenal adenoma (incidentalomas) [13]. Invasive bilateral adrenal vein sampling (AVS) is the current gold-standard diagnostic procedure adopted, with cannulation success rates varying from 8% to 95% [10, 14-16].

Computed tomography (CT) and magnetic resonance imaging (MRI) have been used for non-invasive lateralisation of aldosterone hypersecretion. These show low diagnostic accuracy due to
suboptimal spatial resolution and sensitivity to detect small UAPA (<1 cm) [14, 17-20]. Positron emission tomography (PET) is considered an accurate and non-invasive alternative to AVS in the management of patients with PA and adrenal adenoma [21].

Methyl and ethyl esters of 1-[(1R)-1-phenylethyl]-1H-imidazole-5-carboxylic acid, such as (R)-metomidate (MTO, Fig. 1) and (R)-etomidate (ETO), are a class of compounds that interact with the mitochondrial cytochrome P-450 enzymes (11β-hydroxylase (CYP11B1) and CYP11B2) in the adrenal cortex (IC$_{50}$ for CYP11B1 = 0.24±0.05 nM (MTO) and 0.5±0.2 nM (ETO), IC$_{50}$ for CYP11B2 = 0.59±0.64 nM (MTO) and 1.7±0.9 nM (ETO)) [22-24]. MTO and ETO have been used as template to develop PET radiolabelled radiotracers using β$^+$-emitting radionuclides such as $^{11}$C and $^{18}$F [21, 25, 26].

Bergström et al. have developed $[^{11}$C]MTO (Fig. 1) by radiolabelling the methyl ester group with $^{11}$C. $[^{11}$C]MTO possesses high specific binding to adrenal enzymes in vitro and in non-human primate studies [25, 27, 28]. Blocking experiments using ETO (10 μM) confirmed the specific uptake of $[^{11}$C]MTO to pig adrenal sections [25]. In humans $[^{11}$C]MTO showed high uptake in adrenal glands (SUV ratio of adrenal gland/liver ratio 1.5±0.7, 15–45 min) and high standardised uptake values (SUV) in aldosterone-hypersecreting adenomas [25, 27, 29-31].

Metabolite studies of $[^{11}$C]MTO in humans revealed that unchanged $[^{11}$C]MTO accounted for 40% and 28% of total blood-borne radioactivity at 20 min and 40 min post injection, with two polar metabolites present in the plasma [30]. Although $[^{11}$C]MTO has good imaging properties for visualization of UAPA,[21] novel radiotracers with increased adrenal-to-liver ratio (large liver uptake hampers the assessment of the right adrenal) and a longer half life radionuclide (e.g. $^{18}$F) are needed for a more widespread adoption of this diagnostic approach.
An increased adrenal-to-liver PET signal was achieved by adding a halogen atom (e.g. chlorine or bromine) in the para-position of MTO’s benzene group such as chlorine ([\(^{11}\)C]ClMTO, Fig. 1) and bromine ([\(^{11}\)C]BrMTO, Fig. 1). In rats [\(^{11}\)C]MTO gives an adrenal-to-liver ratio of 3.8 at 30 min post injection, increasing to 4.4 and 7.2 using [\(^{11}\)C]ClMTO and [\(^{11}\)C]BrMTO, respectively [32]. [\(^{11}\)C]MTO is not used in a widespread manner, partly because of its short half-life that limits its use to PET centres with on-site cyclotrons. A MTO analogue with a longer fluorine-18 half-life would enable the examination of more patients per tracer production, and its distribution to PET-centres without on-site cyclotrons.

Wasdak et al. developed an ETO derivative radiolabelled with fluorine-18 ([\(^{18}\)F]FETO, Fig. 1) to enhance the image resolution, and pharmacokinetic and pharmacodynamic properties of [\(^{11}\)C]MTO [33]. MTO and FETO have similar binding affinities to displace the radioligand 4-\([^{131}\)I]iodometomidate ([\(^{131}\)I]IMTO) on homogenized rat adrenal membranes as an acceptable surrogate for testing inhibitory affinity versus CYP11B1 and CYP11B2 (IC\(_{50}\) = 3.69±1.92 nM and 2.9±0.55 nM, respectively) [34]. [\(^{18}\)F]FETO was produced using an automated one-step protocol within 70 min (total synthesis time) with a non-isolated radiochemical yield (RCY) of 20±3% [35]. Regional organ distribution of [\(^{18}\)F]FETO in rat revealed an adrenal-to-liver ratio of 14.48 at 60 minutes post injection [36]. Metabolite analysis indicated that [\(^{18}\)F]FETO is degraded to 2-[\(^{18}\)F]fluoroethanol \textit{in vitro} and \textit{in vivo} [37]. In humans, [\(^{18}\)F]FETO is rapidly metabolised in the first 10 minutes (91% intact [\(^{18}\)F]FETO after 2 minutes; 24% after 10 min, 11% after 20 min and 3.7% after 90 min) [37]. [\(^{11}\)C]MTO and [\(^{18}\)F]FETO showed rapid metabolism \textit{in vivo} corresponding to de-esterification to the non-radioactive and inactive carboxylic acid derivative (IC\(_{50}\)=0.12 mM) [34, 38] and radioactive metabolites, such as [\(^{11}\)C]methanol and
[11C]formaldehyde for [11C]MTO and [18F]fluoroethanol for [18F]FETO, affecting the signal/noise ratio and specificity of the imaging data acquired [30, 36, 37].

A para-fluorinated aromatic (R)-MTO derivative (FAMTO, Fig. 1) has comparable affinity for adrenal enzymes (K_i = 7.3 nM measured using [131I]IMTO) as MTO (K_i = 4.02 ± 1.87 nM) in rat adrenal membranes [39]. We therefore developed a radiosynthetic strategy to produce a [18F]-radiolabelled analogue of MTO ([18F]FAMTO) in order to evaluate it as a potential radiotracer for aldosterone-producing adenomas.

2. Materials & Methods

2.1 General Consideration

[18F]Fluoride ion was produced using an RDS112 cyclotron at King’s College London PET Centre by the 18O(p,n)18F reaction via proton irradiation of enriched (95%) 18O water.

2.2 Trapping and releasing of [18F]Fluoride ion on a Sep-Pak Accell Plus QMA cartridge

0.5–1.5 GBq of aqueous [18F]fluoride ion was trapped in an anion-exchange resin cartridge (Sep-Pak Accell Plus QMA cartridge, WAT023525, Waters) pre-activated with 10 mL 1 N NaHCO3 (aq), 10 mL water (H2O) followed by 10 mL air. The trapped [18F]fluoride ion was released with solution A, composed of 25.5 µmol Kryptofix (K222) and 4.5 µmol KHCO3 in acetonitrile (MeCN): H2O (85:15, 1 mL) or solution B, composed of 19.55 µmol K222 and 0.9 µmol K2CO3 in MeCN:H2O (85:15, 1 mL). The solvent was removed by heating at 90 °C under a stream of N2 and fluoride ion was dried by azeotropic distillation with MeCN (2 x 0.5 mL). Compound 1 (5 mg) was dissolved in anhydrous dimethyl sulfoxide (DMSO, 100-500 µL) and the obtained solution was added to the dried [18F]fluoride ion/K222/K2CO3 mixture. The vial was
then sealed and stirred at 110-180 °C for 15-30 minutes, quenched with H₂O and analysed by radioTLC.

2.3 Radioynthesis of [¹⁸F]FAMTO

*High base procedure:* The trapped [¹⁸F]fluoride ion was released with 0.5 mL of a solution composed of K₂₂₂ (16 μmol) and K₂CO₃ (2.4 μmol) in MeCN: H₂O (80:20). Azeotropic drying was performed by addition of MeCN (2 x 0.5 mL) and heating at 90 °C under a stream of N₂. To the dried mixture, 500 μL of DMF was added. Aliquots of 500, 250, 125 and 87 μL of [¹⁸F]KF/K₂₂₂/K₂CO₃, 2 (6.3 mg, 18 μmol) and tetrakis(pyridine)copper(II) triflate (Cu(OTf)₂(py)₄, 3.6 mg, 5 μmol) were added in a vial. DMF was added to achieve a final volume of 500 μL (see Table 2). Radiofluorination was conducted at 118 °C for 20 min, cooled to room temperature, and diluted with H₂O.

*Low base procedure:* Aqueous [¹⁸F]fluoride ion (100-1000 MBq) was loaded onto a QMA cartridge, the cartridge was flushed with air and the [¹⁸F] elution was performed using 2 mL of K₂₂₂ (1.5 μmol) and K₂CO₃ (0.87 μmol) in MeCN: H₂O (80:20). Azeotropic drying was performed by addition of MeCN (2 x 1 mL) and heating at 90 °C under a stream of N₂. To the dried mixture DMF (500, 300, 200, and 100 μL), 2 (6.3 mg, 18 μmol) and Cu(OTf)₂(py)₄ (3.6 mg, 5 μmol) were added (see Table 2). Radiofluorination was conducted at 118 °C for 20 min under air, cooled to room temperature, and diluted with H₂O.

2.4 Purification and Analysis of [¹⁸F]FAMTO

The crude mixture was purified by semi-preparative HPLC (see Appendix A). The purified [¹⁸F]FAMTO was subsequently diluted with 40 mL of PBS, the solution loaded onto a Sep-Pak tC18 Plus Long SPE Cartridge 900 mg, 37-55 μm (cat. no. WAT036800, Waters) and eluted with ethanol (2 mL). Ten fractions (0.2 mL) were collected and radioactivity determined.
Fractions with highest radioactivity were combined and formulated with saline. The formulated solution (4-6 mL of 10% ethanol in saline) containing 1-10 MBq of $[^{18}\text{F}]$FAMTO was used for \textit{in vitro} and \textit{in vivo} experiments. Analytical reverse-phase HPLC (see Appendix A) was used to determine the molar activity, radiochemical and chemical purity. Identification of the radioactive products was confirmed by co-elution of added non-radioactive compounds.

2.5 Determination of chiral conformation and enantiomeric excess of 2,4 and $[^{18}\text{F}]$FAMTO

Circular dichroism (CD) spectra of $(R)$-ETO (enantiomeric excess (e.e.) > 99%, Sigma Aldrich), $(R)$-2, $(R)$-4 and $(S)$-8 (e.e. > 97%, Sigma Aldrich) were acquired on the Applied Photophysics Ltd Chirascan Plus spectrometer (Fig. S1).

Enantiomeric purity of $(R)$-2, $(R)$-4, $(R)$-5, and $(R)$-$[^{18}\text{F}]$FAMTO was performed on a chiral HPLC Lux 5 µm Cellulose-3 250 x 4.6 mm column (Table S2). Commercial $(R)$-ETO (e.e. > 99%) and $(S)$-8 (e.e. > 97%) were used as control.

2.6 Determination of RCY and molar activity of $[^{18}\text{F}]$FAMTO

The entire quenched reaction mixture was used to determine non-isolated and isolated RCY.

All RCYs are reported as decay corrected values [40]. Non-isolated RCYs were determined by integrating the area under the curve in the preparative radio-HPLC chromatogram or iTLC. Isolated RCY were calculated by relating the amount of isolated $[^{18}\text{F}]$FAMTO to the amount of $[^{18}\text{F}]$fluoride ion trapped on QMA cartridge.

The molar activities (GBq/µmol) were calculated by dividing the radioactivity of $[^{18}\text{F}]$FAMTO by the amount of the unlabeled FAMTO determined from the peak area in the UV-HPLC chromatograms ($\lambda$= 254 nm, common wavelength for identifying metomidate derivative compounds such as etomidate and iodometomidate [25, 38], fig. S1). FAMTO concentrations were determined from a UV-absorbance calibration curve (see Appendix A).
2.7 Pig Organ Tissues

Pig tissues were purchased from Seralab, UK. Adrenal glands, kidneys, and liver were collected from an healthy animal (female, 9 months old). Tissues were delivered at 4 °C in Dulbecco’s media. Once collected, tissues were cut in small and medium pieces. Pieces were snap frozen in an isopentane bath cooled to -30 °C and stored at -80 °C.

2.8 Autoradiography

Frozen sections (20 μm) of pig adrenal glands, kidneys, and liver were prepared in a Cryostat and put on superfrost glass slides. At the start of the experiment, the slides warmed to room temperature and preincubated for 10 min in TRIS buffer (50 mM, pH 7.4). Slides were then transferred to containers containing 1 nM of \([^{18}\text{F}]\text{FAMTO}\) in 40 mL of TRIS buffer (50 mM, pH 7.4). In a duplicate set of containers, 1 μM of MTO was added to block specific binding. After incubation for 30 minutes (the slides were washed 2×3 min in fresh 50 mM TRIS buffer, pH 7.4). The slides were dried and then exposed to phosphor imaging plates (BAS-IP TR 2040, GE Healthcare, UK) for 30 minutes and scanned in a Typhoon 8600 phosphorimager (GE Healthcare, UK). Images (Fig. 2) were analysed using OptiQuant 5.0 software (PerkinElmer, UK).

2.9 Animal Studies

Biodistribution and metabolite studies were carried out in adult male Sprague-Dawley rats (300–400 g). All animal studies were carried out in accordance with the UK Home Office Animals (Scientific Procedures) Act 1986. Experiments complied with UK Research Councils’ and Medical Research Charities’ guidelines on responsibility in the use of animals in bioscience research, under UK Home Office project and personal licenses.
2.10 Ex Vivo Biodistribution

Nine anesthetized rats (2–3% isoflurane/oxygen) were injected intravenously with 1-3 MBq/kg of formulated $[^{18}\text{F}]$FAMTO and sacrificed at 15, 30 and 60 minutes post-injection. The specific uptake of $[^{18}\text{F}]$FAMTO was evaluated in three anesthetized rats (2–3% isoflurane/oxygen) using 1 mg/kg ETO i.v. (95% saline and 5% ethanol) 15 minutes before $[^{18}\text{F}]$FAMTO injection (1-3 MBq/kg), and animals sacrificed 30 minutes post radiotracer injection. Tissues including whole brain, heart, lungs, stomach, liver, spleen, small intestine, large intestine, kidneys, bladder, thigh bone, adrenal glands, and testes were excised. Urine and blood were also collected. All samples were weighed and radioactivity content measured using an automated well counter with a standard dilution of $[^{18}\text{F}]$FAMTO. Counts were decay-corrected and the %ID/g calculated (Fig. 3A and Table S1). Data are expressed as mean ± standard error (SE) from three independent replicates, unless otherwise indicated. Statistical analysis of %ID/g in the biodistribution study was performed with IBM SPSS Statistics (version 24). Student t-tests were used to determine statistical significance with P < 0.05 considered significant.

2.11 Analysis of Radiolabelled Metabolites in Rats

Blood and urine samples were collected at 10, 30, and 60 minutes post injection to measure the amounts of unchanged tracer and radioactive metabolites. Blood was centrifuged at 6000 rpm for 5 min, the supernatant was treated with MeCN (1:1) and centrifuged to precipitate plasma proteins. Plasma supernatant and urine samples were then injected into an HPLC semi-preparative column (see Appendix A), and the eluate collected in 1.5 mL test tubes and gamma-counted. Two metabolites ($t_R = 3$ and 21 minutes) and $[^{18}\text{F}]$FAMTO were observed in the plasma (Fig. 4). One metabolite ($t_R = 3$ minutes) was observed in the urine (Fig. S2). 2.5 μL aliquots of radioactivity eluting at $t_R = 3$ minutes and compound 12 (Scheme 1) were analysed by TLC.
plates (Merck F-254 silica gel) eluted with dichloromethane:methanol:trifluoroacetic acid (TFA) (8:2:0.05). TLC plates were scanned in a Typhoon 8600 phosphorimager (GE Healthcare, UK) and analysed using OptiQuant 5.0 software (PerkinElmer, UK).

2.12 Stability Studies in Plasma

Human blood (1 mL) was incubated with 0.7-1 MBq (200 µL) \[^{18}\text{F}\]FAMTO at room temperature for 10 and 20 minutes. After incubation, plasma was separated by centrifugation (5 min, 4000×g) and the proteins were precipitated by the addition of an equal volume of MeCN. The tubes were centrifuged for 5 min at 4000×g. The supernatant was then injected onto the HPLC (HPLC method 1) and serial 1.5 mL HPLC fractions were collected and gamma-counted. \[^{18}\text{F}\]FAMTO (0.7-1 MBq, 200 µL) incubated in PBS (1 mL) was used as control.

2.13 Plasma Protein Binding

The plasma protein binding of \[^{18}\text{F}\]FAMTO was measured in the plasma of blood samples. Plasma was prepared from fresh human blood by centrifugation (5 min, 4000×g) at room temperature. Two vials containing fresh human plasma (300 µL) and PBS (300 µL, control) were incubated at room temperature with 30 µL of a solution containing \[^{18}\text{F}\]FAMTO (1-2 MBq). After 10 minutes, each solution was sampled and counted. The solution (200 µL) was injected into a filter device (Millipore Centrifree tubes, YM-30) and subsequently centrifuged for 5 minutes at 6000 rpm. The solution passed through a centrifugal filters unit (nominal molecular weight limit 30,000 Dalton) and the filtrate and control samples were gamma-counted.

2.14 PET Imaging

PET-CT scans were performed on a BioScan nanoPET-CT® PLUS (Mediso, Hungary) scanner using their proprietary acquisition software (Nucline 1.07). The rats were anaesthetised and
maintained at 2.5% isofluorane and 1 L/min flow of Oxygen (O₂). A CT scan was acquired prior to the commencement of the PET scan. Dynamic PET scans were acquired for 60 minutes post intra-venous (IV) administration by tail vein injection of [¹⁸F]FAMTO (1.0 MBq, n=2) or by pre-administration ETO (1 mg/Kg) 15 minutes prior to [¹⁸F]FAMTO injection (1.0 MBq, n=1).

PET scans were reconstructed using Tera-Tomo 3D image reconstruction algorithm. Reconstructions were performed with the detector coincidence mode set at 1:3. Corrections for decay, randoms, crystal dead time, detector normalization and, attenuation correction was implemented. A total of 6 subsets and 4 iterations were applied resulting in a voxel size of 0.25×0.25×0.25 mm³ for CT, and 0.4×0.4×0.4 mm³ for PET. The PET and CT images were co-registered automatically. Image analysis was performed using pre-clinical image post processing software VivoQuant™.

3. Results

3.1 Chemistry

 Aryl sulfonium salt 1 (Scheme 1) was synthesised following the procedure reported by Sander et al. [41]. The thioether 5 reacted with diaryliodonium triflate under copper(II) catalysis (125 °C, 1 h) giving 1 in 53% yield. Pinacol boronate ester 2 was prepared by the following procedure adapted from the literature [42]. The para-bromo MTO derivative (6) reacted with bis(pinacolato)diboron in the presence of potassium acetate and Pd-catalyst to form 2 with a yield of 76±10% (n=3).

Scheme 1 shows the route used to synthesize 3-6 via Mitsunobu reaction that involves the use of both an oxidising agent such as di-tert-butyl azodicarboxylate (DtBad) and a reducing agent such as triphenylphosphine (PPh₃) under mild conditions. Yields between 40-60% were obtained.

3.2 Radiosynthesis of [¹⁸F]FAMTO
Two $^{18}$F-labeling strategies were selected to produce $[^{18}$F]FAMTO, the first via an aryl sulfonium salt (1, Scheme 1) and the second via an aryl boronic precursor (2).

The strategy of labeling sulfonium salts with $^{18}$F fluoride ion has been reported to be a direct, straightforward nucleophilic substitution [41]. Following the optimised procedure developed by Sander et al., dimethyl sulfoxide (DMSO), potassium bicarbonate (KHCO$_3$, 30 mM), Kryptofix (K$_{222}$, 30 mM) and 1 (5 mg) in 500 μL DMSO at 110 °C for 15 minutes, $[^{18}$F]FAMTO was obtained with very low non-isolated radiochemical yield (RCY, 1%, entry 1, Table 1).

Screening of solvent volume, time and bases commonly used for nucleophilic substitution reactions with $[^{18}$F]fluoride ion was investigated in an attempt to improve the RCY. Increasing the concentration of precursor from 0.01 mg/mL to 0.02 mg/mL (entry 2) or increasing the reaction time from 15 to 30 minutes (entry 3) did not give the desired product. By substituting KHCO$_3$ with K$_2$CO$_3$, $[^{18}$F]FAMTO was obtained using 500 and 250 μL of DMSO with a non-isolated RCY of 8% and 7%, respectively (entries 4-5). Decreasing further the volume of DMSO to 100 μL caused a RCY drop (entry 6). Increasing the temperature from 110 to 150 or 180 °C, afforded no $[^{18}$F]FAMTO whatsoever.

An alternative radiolabelling strategy to produce $[^{18}$F]FAMTO was subsequently investigated starting from the aryl boronic derivative 2. Initially, the experiment was performed by mixing a solution of 2 and Cu(OTf)$_2$(py)$_4$ in DMF with the dried residue of $[^{18}$F]fluoride ion/K$_{222}$/K$_2$CO$_3$ and heated at 110 °C for 20 min under air. The formation of $[^{18}$F]FAMTO under these conditions was not observed (entry 1, Table 2).

Neumaier and coworkers have reported an efficient protocol to increase the RCY of copper-mediated aromatic radiofluorination using a “low amount of base” strategy [43]. Indeed using small amount of K$_{222}$/K$_2$CO$_3$ in DMF obtained by aliquoting the dried residue of $[^{18}$F]fluoride
ion/K$_{222}$/K$_2$CO$_3$ (K$_{222}$= 10 µmol and K$_2$CO$_3$ = 6 µmol), a selective $^{18}$F-incorporation was observed affording [$^{18}$F]FAMTO with a non-isolated RCY of 17% (entry 2, Table 2). As the “low base” approach gave promising results, we further reduced the amount of K$_{222}$ and K$_2$CO$_3$ present in the reaction solution. Decreasing 2- and 4-times the amount of K$_{222}$ and K$_2$CO$_3$, [$^{18}$F]FAMTO was produced with a RCY between 16-23% (entries 3-4, Table 2).

Subsequent experiments were performed using the same amount of K$_2$CO$_3$ and K$_{222}$ for [$^{18}$F]fluoride ion elution and radiofluorination reaction allowing an easy transferability of manual procedures to automated synthesis modules. [$^{18}$F]Fluoride ion was eluted from an anion exchange resin with a solution of K$_2$CO$_3$ (0.87 µmol) and K$_{222}$ (1.5 µmol) dissolved in MeCN:H$_2$O. Following the solvent evaporation, a solution of Cu(OTf)$_2$(py)$_4$ and 2 in 500 µL DMF was added to the dried residue of [$^{18}$F]fluoride ion/K$_{222}$/K$_2$CO$_3$ and the reaction mixture heated at 110 °C for 20 minutes. [$^{18}$F]FAMTO was produced with non-isolated RCY of 32 ± 6% (entry 5). We next optimized the reaction with respect to solvent volume. Decreasing the volume of DMF from 500 to 300 and 200 µL (entries 6-7), the RCY of [$^{18}$F]FAMTO remained the same. However a further decrease of the volume to 150 µL (entry 8), resulted in a non-isolated RCY drop from 32% to 11%. The synthesis, purification/reformulation and quality control time for the preparation of [$^{18}$F]FAMTO are 75, 25 and 20 minutes, respectively. The radiosynthesis of [$^{18}$F]FAMTO was achieved with an overall decay-corrected RCY of isolated [$^{18}$F]FAMTO of 18 ± 2%, >99% RCP, >99% e.e. and 105 ± 39 GBq/µmol molar activity within 120 minutes of work, starting from 850-734 MBq of $^{18}$F-fluoride.

3.3 In vitro autoradiography
The *in vitro* binding of [*18*F]FAMTO was evaluated by autoradiography using pig adrenal, kidney and liver tissues. The incubation of adrenal gland sections with [*18*F]FAMTO showed a high specific binding with the signal of [*18*F]FAMTO completely blocked with 1 µM of MTO. Both liver and kidney organ samples were selected due to their known role in [*11*C]MTO metabolism and excretion [25]. Blocking studies revealed a high specific binding in the liver and kidney, organs known to be rich in cytochrome P450 enzymes.

### 3.4 Ex Vivo Biodistribution, metabolite analysis and in vivo PET Imaging Studies in Rats

*Ex vivo* biodistribution data (Fig. 3A and Table S1), performed in healthy Sprague-Dawley rats, was used to assess the adrenal uptake as well as the adrenal-to-organ ratio. [*18*F]FAMTO showed high liver uptake in the first 10 minutes (%ID/g = 3.61 ± 1.53) followed by a slight decrease at 30 min (%ID/g = 2.16 ± 1.53) and 60 min (%ID/g = 1.68 ± 0.18). Adrenal uptake increased slowly during the first 30 minutes up to %ID/g = 6.2 ± 0.46, followed by a slow decrease up to %ID/g = 4.92 ± 0.70 at 60 minutes. Adrenal-to-liver ratio increased from 0.66 at 10 minutes to 2.8 at 30 minutes post-injection (Fig. 3A and Table S1).

Rats that received ETO (1 mg/kg) 10 minutes prior to injection of [*18*F]FAMTO showed a significant decrease in liver uptake (66%, p = 0.005, see Table S1) and a moderate decrease in the adrenal glands (39%, p = 0.03). Pre-treatment with ETO increased the ratio of %ID/g in adrenal to liver by 38% (p = 0.12) leading to an enhanced adrenal-to-liver PET signal compared to the non-pre-treatment group. An in vivo PET image of the adrenal uptake of [*18*F]FAMTO after pre-treatment with ETO (1 mg/kg) is shown in Fig. 3B and S4.

Plasma metabolite analysis revealed 13%, 8% and 2% of unchanged [*18*F]FAMTO at 10, 30 and 60 minutes post-injection, respectively. Two hydrophilic metabolites at retention times 3 and 21 minutes were observed (Fig. 4). The metabolite eluting at 3 minutes has been identified as the free acid [*18*F]12
(Fig. S3). Urine metabolite analysis revealed only one metabolite in solution corresponding to $[^{18}\text{F}]$MTO (Fig. S2).

### 3.5 Stability Studies in Human Blood And Plasma Free Fraction

Plasma-derived metabolites can cause a non-specific signal that reduces the specificity and quality of PET imaging endpoints. Metabolite studies of $[^{11}\text{C}]$MTO or $[^{18}\text{F}]$FETO in humans revealed that unchanged radiotracer accounted for 40% and 11% of total blood-borne radioactivity at 20 min post injection, respectively and, considering the rapid in vivo metabolism of both radiotracers [30, 37], we decided to perform $[^{18}\text{F}]$FAMTO metabolite studies over a similar (20 minutes) timeframe for comparison. No degradation of $[^{18}\text{F}]$FAMTO was observed after incubation in human blood for 20 minutes. The plasma free fraction of $[^{18}\text{F}]$FAMTO was determined to be $37.55 \pm 5.78\%$ (mean ± SD, n=5) by ultrafiltration.

### 4. Discussion

The development of the novel $^{18}\text{F}$ radiotracer targeting adrenal gland enzymes represents a valuable advancement to the field of PA PET imaging. Our PET radiotracer development approach started from the structure-activity relationship analysis of MTO ($K_i = 4.02 \pm 1.87$ nM), a potent inhibitor of CYP11B1 and CYP11B2 adrenal gland enzymes, and its derivatives bearing a halogen atom on the benzene ring (e.g. Br, I and F). $[^{11}\text{C}]$MTO is a prototype radiotracer offering a rapid non-invasive procedure localizing aldosterone-producing adenomas [21, 44]. MTO derivatives bearing an iodine, bromine or fluorine atom in the 4-position of the benzene ring ($K_i = 8.7 \pm 3.2$ nM, $8.8 \pm 2.4$ nM and $8.15 \pm 0.85$ nM, respectively) have similar inhibitory activity to MTO, indicating that structural modification on the benzene ring does not significantly impact the affinity to the target’s
binding pocket [24, 34, 39]. These results encouraged us to attach a fluorine-18 atom at para-position of the MTO benzene ring generating a novel PET radiotracer ([18]FAMTO, Fig. 1).

Initial investigations, focused on using previously recognised strategies to incorporate fluorine-18 into aromatic rings in a one-step reaction using synthetically accessible precursors such as aryl sulfonium salt 1 or an aryl boronic precursor 2 to obtain the R-enantiomer of [18]FAMTO. The R-configuration of MTO (IC$_{50}$ = 3.69 ± 1.92 nM) is a 130 times more potent an inhibitor than its S-enantiomer (IC$_{50}$ = 492 ± 281 nM) [34].

Using the aryl sulfonium strategy, a benzylic 1H-imidazole derivative, ETO fragment, has been radiolabelled by Sander et al. in 31% RCY [41]. Applying the same conditions to 1, the production of [18]FAMTO was not achieved. Following a procedure developed by Mu et al. [45] that uses K$_2$CO$_3$ instead of KHCO$_3$ and lowering the base concentration from 15 to 6 μmol, [18]FAMTO was obtained in low non-isolated RCY (7 ± 2 %).

An alternative radiolabelling strategy to produce [18]FAMTO was subsequently investigated starting from the aryl boronic derivative 2. When the dried residue of [18]F fluoride ion/K$_{222}$/K$_2$CO$_3$ is taken up in a solution in DMF in the presence of copper-catalyst and 2, the $^{18}$F-incorporation was not observed. A similar trend was observed by Neumaier et al. who demonstrated that large quantities of K$_2$CO$_3$ to elute [18]F fluoride ion from ion exchange cartridges impacts negatively on copper-mediated radiofluorination reactions, decreasing the RCY of the desired radiotracer [43]. Indeed using small aliquots of K$_{222}$/K$_2$CO$_3$ in DMF obtained by dissolving the dried residue of [18]F fluoride ion/K$_{222}$/K$_2$CO$_3$, a selective $^{18}$F-incorporation was observed affording [18]FAMTO with an overall decay-corrected RCY of isolated [18]FAMTO of 18%.
In vitro autoradiography on pig adrenal, liver and kidney sections, initially used to characterise the binding properties of $[^{18}\text{F}]$FAMTO, demonstrated that $[^{18}\text{F}]$FAMTO bound specifically to adrenal gland enzymes and that binding was completely blocked using 1 μM of MTO.

The simplicity of radiolabelling and encouraging results from in vitro studies justified further evaluation of the new tracer in vivo. Clinically desirable features for a PET radiotracer to be used in the identification of adenomas include high and specific radioactivity concentration in adrenal glands, rapid renal excretion, and low non-specific uptake of $[^{18}\text{F}]$FAMTO in non-target tissues (e.g. liver, bone).

In vivo studies confirmed the high specificity of $[^{18}\text{F}]$FAMTO uptake in adrenal glands showing a ratio of adrenal-liver uptake of 2.81 at 30 minutes post injection, which is similar to the adrenal gland-to-liver ratio of $[^{11}\text{C}]$MTO in rats (3.8 at 30 min) [46]. This ratio would be expected to be elevated in the presence of UAPA due to an overexpression of adrenal enzymes [8, 47].

Image analysis of the rats administered with $[^{18}\text{F}]$FAMTO was hampered by the high liver uptake masking the signal of the right adrenal gland. The pre-treatment of ETO 15 minutes prior to $[^{18}\text{F}]$FAMTO-injection lowered the liver uptake and increased the signal adrenal gland-to-liver of $[^{18}\text{F}]$FAMTO (Fig. 3B and S4). Because of the known rapid metabolism of ETO in vivo [48-50], it is not expected that pre-treatment with 1 mg/kg ETO will cause complete blockade. However, in vitro, in the absence of MTO metabolism, 1 μM MTO was sufficient to fully block $[^{18}\text{F}]$FAMTO specific binding.

High radioactivity was observed in the urine (urine-blood ratio was 4.36, 24.9 and 49.1 at 10, 30 and 60 minutes, respectively). Conversely, no uptake was visualised in bone, indicating an absence of $[^{18}\text{F}]$FAMTO defluorination.
A metabolite study collecting rat blood samples after \(^{18}\text{F}\text{FAMTO}\) injection revealed that 13% of radioactivity after 10 minutes was due to \(^{18}\text{F}\text{FAMTO}\) (Fig. 4). The main metabolite in plasma and urine was identified to be the carboxylic acid of \(^{18}\text{F}\text{FAMTO}\) (Fig. 4, Fig. S2 and S3). In analogy to the carboxylic acid derivative of MTO, we anticipate that compound 12 would also have negligible affinity for adrenal gland enzymes [34]. Low metabolic stability of MTO and FETO has been observed \textit{in vitro} and \textit{in vivo} [30, 37]. However, in humans \(^{18}\text{F}\text{FETO}\) is metabolised faster than \(^{11}\text{C}\text{MTO}\). At 20 minutes post injection, the unchanged \(^{18}\text{F}\text{FETO}\) is 11% whereas \(^{11}\text{C}\text{MTO}\) is 40% of total radioactivity [30, 37]. The methyl-ester \(^{18}\text{F}\text{FAMTO}\) might have the same profile as \(^{11}\text{C}\text{MTO}\), rather then the ethyl-ester \(^{18}\text{F}\text{FETO}\), however this hypothesis needs to be confirmed by determining \(^{18}\text{F}\text{FAMTO}\) radiometabolic profile in humans. Blood-borne esterases might also produce radiometabolites to generate a non-specific background signal, reducing the specificity and quality of PET imaging endpoints. Because of this the stability of \(^{18}\text{F}\text{FAMTO}\) was evaluated in human plasma revealing that \(^{18}\text{F}\text{FAMTO}\) is highly stable in human plasma and blood.

5. CONCLUSION

\(^{18}\text{F}\text{FAMTO}\), a new \(^{18}\text{F}\)-labelled analogue of \((R)-\text{MTO}\) was synthesized in a one-step radiofluorination procedure in good yields. The method utilises a synthetically accessible boronic ester precursor 2, produced in a one-step reaction. A low base protocol is crucial for successful \(^{18}\text{F}\text{FAMTO}\) labelling. \textit{In vitro} and \textit{in vivo} experiments have shown that \(^{18}\text{F}\text{FAMTO}\) accumulates in adrenal glands, with good adrenal-to-liver ratios in rodents and a good radiometabolic profile with slow kinetics in the adrenals and rapid kinetics in the liver. The simplicity of radiolabelling and encouraging preclinical results justify progression to toxicology
safety assessment studies and translation of $[^{18}\text{F}]\text{FAMTO}$ to healthy volunteers and patients with adrenal lesions of different adrenocortical and non-adrenocortical origin.
Fig. 1. Chemical structures of ETO, MTO, \([^{11}\text{C}]\text{MTO}\), \([^{11}\text{C}]\text{BrMTO}\), \([^{11}\text{C}]\text{ClMTO}\), \([^{18}\text{F}]\text{FETO}\), and \([^{18}\text{F}]\text{FAMTO}\).
Fig. 2. Frozen tissue-section autoradiography of $[^{18}\text{F}]\text{FAMTO}$ (1 nM) binding to pig adrenal, pig liver, pig kidney. Lower panel $[^{18}\text{F}]\text{FAMTO}$ (1 nM) blocking studies using 1 μM MTO.
Fig. 3. (A) Organ uptake of [18F]FAMTO (i.v.) in male Sprague Dawley rats (n=3, for each group) at 10, 30, 60 minutes post injection. Rats pre-treated with ETO (1 mg/Kg, i.v.) 15 min prior to [18F]FAMTO i.v. injection and culled after 30 minutes. A two-tailed paired Student’s t test was used to compare adrenal-liver uptake and adrenal uptake in rats pre-treated with ETO versus that of control rats. (B) In vivo PET imaging of a male Sprague Dawley rats showing adrenal uptake of [18F]FAMTO after pre-treatment with ETO (1 mg/kg).
Fig. 4. Plasma metabolite analysis of $[^{18}\text{F}]$FAMTO in male Sprague Dawley rats at 10, 30, 60 minutes post radiotracer injection.
**Scheme 1.** Reaction scheme for production of MTO, FAMTO, 12, and $[^{18}\text{F}]$FAMTO. a: DtBAD, PPh$_3$, THF, 0 °C, rt, 17 h; b: Ph$_2$ITfO, Cu(C$_6$H$_5$COO)$_2$ TFSA, PhCl, 125 °C, 2 h; c: (BPin)$_2$, KOAc, (C$_{17}$H$_{14}$P)$_2$Fe · PdCl$_2$, DMSO, 80 °C, 15 h; d: $[^{18}\text{F}]$fluoride ion, DMSO, 110 °C, 14-30 min; e: $[^{18}\text{F}]$fluoride ion, Cu(Py)$_4$(OTf)$_2$, DMF, 110 °C, 20 min; f: NaOH 2N, MeOH, rt, 17 h.
**Table 1.** Radiosynthesis of $[^{18}\text{F}]$FAMTO from 1.

| Entry | Releasing solution | Time (min) | Volume (mL) | Temperature (°C) | Non-isolated RCY (%)<sup>c</sup> |
|-------|--------------------|------------|-------------|------------------|----------------------------------|
| 1     | A<sup>a</sup>      | 15         | 500         | 110              | 1 ± 0.5 (n=3)                    |
| 2     | A                  | 15         | 250         | 110              | 0 (n=2)                          |
| 3     | A                  | 30         | 250         | 110              | 0 (n=2)                          |
| 4     | B<sup>b</sup>      | 30         | 500         | 110              | 8 (n=1)                          |
| 5     | B                  | 30         | 250         | 110              | 7 ± 2 (n=3)                      |
| 6     | B                  | 30         | 100         | 110              | 1, 4 (n=2)                       |
| 7     | B                  | 30         | 250         | 150              | 0 (n=1)                          |
| 8     | B                  | 30         | 250         | 180              | 0 (n=1)                          |

<sup>a</sup>Solution A: 0.5 mL $\text{K}_2\text{CO}_3$ (30 mM) and KHCO<sub>3</sub> (30 mM) in MeCN:H<sub>2</sub>O (85:15).

<sup>b</sup>Solution B: 1 mL of $\text{K}_2\text{CO}_3$ (23 mM) and K<sub>2</sub>CO<sub>3</sub> (6 mM) in MeCN:H<sub>2</sub>O (85:15).

<sup>c</sup>Determined by radio-TLC (% ± SEM).
Table 2. Optimization of radiofluorination of 2 to form $[^{18}\text{F}]$FAMTO.

| Entry | K$_{222}$ (µmol) | K$_2$CO$_3$ (µmol) | Activity released from QMA (%) | K$_{222}$ (µmol) | K$_2$CO$_3$ (µmol) | Volume (DMF) | Non-isolated RCY (%) | Isolated RCY (%) |
|-------|------------------|--------------------|-------------------------------|------------------|--------------------|--------------|----------------------|------------------|
| 1     | 20               | 12                 |                               | 20               | 12                 | 500          | 0 (n=2)              | n.d.             |
| 2     | 20               | 12                 | 95 ± 4 (n=8)                  | 10               | 6                  | 500          | 17, 16 (n=2)         | n.d.             |
| 3     | 20               | 12                 |                               | 5                 | 3                  | 500          | 18, 16 (n=2)         | n.d.             |
| 4     | 20               | 12                 |                               | 3                 | 1.5                | 500          | 22, 23 (n=2)         | n.d.             |
| 5     | 1.5              | 0.87               |                               | 1.5              | 0.87               | 500          | 32 ± 6 (n=5)         | 28 ± 14 (n=5)    |
| 6     | 1.5              | 0.87               | 82 ± 2 (n=27)                 | 1.5              | 0.87               | 300          | 29 ± 7 (n=3)         | n.d.             |
| 7     | 1.5              | 0.87               |                               | 0.87             | 200                | 200          | 32 ± 2 (n=18)        | 18 ± 2 (n=18)    |
| 8     | 1.5              | 0.87               |                               | 0.87             | 150                | 150          | 11 (n=1)             | n.d.             |

*a* 2 (18 µmol), Cu(OTf)$_2$(py)$_4$ (5 µmol), DMF (150-500 uL), 20 min, 110 °C.

*b* Estimated by analytical radio-HPLC of the crude product (% ± SEM).

*c* Calculated from the amount of isolated $[^{18}\text{F}]$FAMTO to the initial amount of $[^{18}\text{F}]$fluoride ion trapped in the Sep-Pak Accell Plus QMA cartridge (% ± SEM).
Appendix A. Supplementary data

The following is the Supplementary data to this article.

ACKNOWLEDGMENT

This work was supported by Medical Research Council (MRC, MR/K022733/1) and Wellcome/EPSRC Centre for Medical Engineering [WT 203148/Z/16/Z]. The authors acknowledge financial support from the Department of Health via the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award to Guy's & St Thomas' NHS Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust and the Centre of Excellence in Medical Engineering funded by the Wellcome Trust and EPSRC under grant number WT 088641/Z/09/Z.
References

[1] Fritsch Neves M and Schiffrin EL Aldosterone: a risk factor for vascular disease Curr Hypertens Rep, 5 (2003), pp. 59-65.
[2] Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, and Mourad JJ Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism J Am Coll Cardiol, 45 (2005), pp. 1243-8.
[3] Briet M and Schiffrin EL Aldosterone: effects on the kidney and cardiovascular system Nat Rev Nephrol, 6 (2010), pp. 261-73.
[4] Powlson AS, Gurnell M, and Brown MJ Nuclear imaging in the diagnosis of primary aldosteronism Curr Opin Endocrinol Diabetes Obes, 22 (2015), pp. 150-6.
[5] Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline J Clin Endocrinol Metab, 93 (2008), pp. 3266-81.
[6] Omura M, Saito J, Yamaguchi K, Kakuta Y, and Nishikawa T Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan Hypertens Res, 27 (2004), pp. 193-202.
[7] Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients J Am Coll Cardiol, 48 (2006), pp. 2293-300.
[8] Fallo F, Pezzi V, Barzon L, Mulatero P, Veglio F, Sonino N, et al. Quantitative assessment of CYP11B1 and CYP11B2 expression in aldosterone-producing adenomas Eur J Endocrinol, 147 (2002), pp. 795-802.
[9] Rossi GP A comprehensive review of the clinical aspects of primary aldosteronism Nat Rev Endocrinol, 7 (2011), pp. 485-95.
[10] Monticone S, Satoh F, Dietz AS, Goupil R, Lang K, Pizzolo F, et al. Clinical Management and Outcomes of Adrenal Hemorrhage Following Adrenal Vein Sampling in Primary Aldosteronism Hypertension, 67 (2016), pp. 146-52.
[11] Mulatero P, Tizzani D, Viola A, Bertello C, Monticone S, Mengozzi G, et al. Prevalence and characteristics of familial hyperaldosteronism: the PATOGEN study (Primary Aldosteronism in TOrino-GENetic forms) Hypertension, 58 (2011), pp. 797-803.
[12] Funder JW, Carey RM, Mantero F, Murad MH, Reinecke M, Shibata H, et al. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline J Clin Endocrinol Metab, 101 (2016), pp. 1889-916.
[13] Hennings J, Hellman P, Ahlstrom H, and Sundin A Computed tomography, magnetic resonance imaging and 11C-metomidate positron emission tomography for evaluation of adrenal incidentalomas Eur J Radiol, 69 (2009), pp. 314-23.
[14] Buffolo F, Monticone S, Williams TA, Rossato D, Burrello J, Tetti M, et al. Subtype Diagnosis of Primary Aldosteronism: Is Adrenal Vein Sampling Always Necessary? Int J Mol Sci, 18 (2017), pp.
[15] Young WF, Stanson AW, Thompson GB, Grant CS, Farley DR, and van Heerden JA Role for adrenal venous sampling in primary aldosteronism Surgery, 136 (2004), pp. 1227-35.
[16] Vonend O, Ockenfels N, Gao X, Alloio B, Lang K, Mai K, et al. Adrenal venous sampling: evaluation of the German Conn's registry Hypertension, 57 (2011), pp. 990-5.
[17] Gavras I The incidentally discovered adrenal mass N Engl J Med, 356 (2007), pp. 2005-6.
[18] Young WF, Jr. Clinical practice. The incidentally discovered adrenal mass N Engl J Med, 356 (2007), pp. 601-10.
[19] Mulatero P, Dluhy RG, Giacchetti G, Boscaro M, Veglio F, and Stewart PM Diagnosis of primary aldosteronism: from screening to subtype differentiation Trends Endocrinol Metab, 16 (2005), pp. 114-9.
[20] Herr K, Muglia VF, Koff WJ, and Westphalen AC Imaging of the adrenal gland lesions Radiol Bras, 47 (2014), pp. 228-39.
[21] Burton TJ, Mackenzie IS, Balan K, Koo B, Bird N, Soloviev DV, et al. Evaluation of the sensitivity and specificity of (11)C-metomidate positron emission tomography (PET)-CT for lateralizing aldosterone secretion by Conn's adenomas J Clin Endocrinol Metab, 97 (2012), pp. 100-9.
[22] Vanden Bossche H, Willemsens G, Cools W, and Bellens D Effects of etomidate on steroid biosynthesis in subcellular fractions of bovine adrenals Biochem Pharmacol, 33 (1984), pp. 3861-8.
[23] Hu Q, Yin L, and Hartmann RW Aldosterone synthase inhibitors as promising treatments for mineralocorticoid dependent cardiovascular and renal diseases J Med Chem, 57 (2014), pp. 5011-22.
[24] Roumen L, Sanders MPA, Pieterse K, Hilbers PAJ, Plate R, Custers E, et al. Construction of 3D models of the CYP11B family as a tool to predict ligand binding characteristics J Comput Aid Mol Des, 21 (2007), pp. 455-71.
[25] Bergstrom M, Bonasera TA, Lu L, Bergstrom E, Backlin C, Juhlin C, et al. In vitro and in vivo primate evaluation of carbon-11-etomidate and carbon-11-metomidate as potential tracers for PET imaging of the adrenal cortex and its tumors J Nucl Med, 39 (1998), pp. 982-9.
[26] Abe T, Naruse M, Young WF, Jr., Kobashi N, Doi Y, Izawa A, et al. A Novel CYP11B2-Specific Imaging Agent for Detection of Unilateral Subtypes of Primary Aldosteronism J Clin Endocrinol Metab, 101 (2016), pp. 1008-15.
[27] Bergstrom M, Juhlin C, Bonasera TA, Sundin A, Rastad J, Akerstrom G, et al. PET imaging of adrenal cortical tumors with the 11beta-hydroxylase tracer 11C-metomidate J Nucl Med, 41 (2000), pp. 275-82.
[28] Khan TS, Sundin A, Juhlin C, Langstrom B, Bergstrom M, and Eriksson B 11C-metomidate PET imaging of adrenocortical cancer Eur J Nucl Med Mol Imaging, 30 (2003), pp. 403-10.
[29] Hennings J, Lindhe O, Bergstrom M, Langstrom B, Sundin A, and Hellman P [11C]metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings J Clin Endocrinol Metab, 91 (2006), pp. 1410-4.
[30] Minn H, Salonen A, Friberg J, Roivainen A, Viljanen T, Langsjo J, et al. Imaging of adrenal incidentalomas with PET using 11C-metomidate and (18)F-FDG J Nucl Med, 45 (2004), pp. 972-9.
[31] Bergstrom M, Sorensen J, Kahn TS, Juhlin C, Eriksson B, Sundin A, et al. PET with [11C]-Metomidate for the Visualization of Adrenocortical Tumors and Discrimination from Other Lesions Clin Positron Imaging, 2 (1999), pp. 339.
[32] Karimi F, Erlandsson M, Lindhe O, and Langstrom B **Synthesis of 11C-labelled metomidate analogues as adrenocortical imaging agents** J Label Compd Radiopharm, 51 (2008), pp. 273-6.

[33] Wadsak W and Mitterhauser M **Synthesis of [18F]FETO, a novel potential 11-β hydroxylase inhibitor** J Label Compd Radiopharm, 46 (2003), pp. 379-88.

[34] Zolle IM, Berger ML, Hammerschmidt F, Hahner S, Schirbel A, and Peric-Simov B **New selective inhibitors of steroid 11beta-hydroxylation in the adrenal cortex. Synthesis and structure-activity relationship of potent etomidate analogues** J Med Chem, 51 (2008), pp. 2244-53.

[35] Rahman O, Erlandsson M, Blom E, and Langstrom B **Automated synthesis of F-18-labelled analogs of metomidate, vorozole and harmine using commercial platform** J Label Compd Radiopharm, 53 (2010), pp. 169-71.

[36] Erlandsson M, Karimi F, Lindhe O, and Langstrom B **18F-labelled metomidate analogues as adrenocortical imaging agents** Nucl Med Biol, 36 (2009), pp. 435-45.

[37] Ettlinger DE, Wadsak W, Mien LK, Machek M, Wabnegger L, Rendl G, et al. **[18F]FETO: metabolic considerations** Eur J Nucl Med Mol Imaging, 33 (2006), pp. 928-31.

[38] Schirbel A, Zolle I, Hammerschmidt F, L. BM, D. S, H. K, et al. **[123/131I]Iodometomidate as a radioligand for functional diagnosis of adrenal disease: synthesis, structural requirements and biodistribution.** Radiochimica Acta, 92 (2009), pp. 297-303.

[39] Berger ML, Hammerschmidt F, Qian R, Hahner S, Schirbel A, Stichelberger M, et al. **[(3)H]metyrapol and 4-[131]Iiodometomidate label overlapping, but not identical, binding sites on rat adrenal membranes** Mol Pharm, 10 (2013), pp. 1119-30.

[40] Coenen HH, Gee AD, Adam M, Antoni G, Cutler CS, Fujibayashi Y, et al. **Consensus nomenclature rules for radiopharmaceutical chemistry - Setting the record straight** Nucl Med Biol, 55 (2017), pp. v-xi.

[41] Sander K, Gendron T, Yiannaki E, Cybulska K, Kalber TL, Lythgoe MF, et al. **Sulphonium Salts as Leaving Groups for Aromatic Labelling of Drug-like Small Molecules with Fluorine-18** Sci Rep-Uk, 5 (2015), pp.

[42] Mossine AV, Brooks AF, Makaravage KJ, Miller JM, Ichiiishi N, Sanford MS, et al. **Synthesis of [18F]Arenes via the Copper-Mediated [18F]Fluorination of Boronic Acids** Org. Lett., 17 (2015), pp. 5780-3.

[43] Zlatopolskiy BD, Zischler J, Krapf P, Zarrad F, Urusova EA, Kordys E, et al. **Copper-Mediated Aromatic Radiofluorination Revisited: Efficient Production of PET Tracers on a Preparative Scale** Chem Eur J, 21 (2015), pp. 5972-9.

[44] Mendichovszky IA, Powlson AS, Manavaki R, Aigbirhio FI, Cheow H, Buscombe JR, et al. **Targeted Molecular Imaging in Adrenal Disease-An Emerging Role for Metomidate PET-CT Diagnostics (Basel),** 6 (2016), pp. 42.

[45] Mu L, Fischer CR, Holland JP, Becaud J, Schubiger PA, Schibli R, et al. **18F-Radiolabeling of Aromatic Compounds Using Triarylsulphonium Salts** Eur J Org Chem, (2012), pp. 889-92.

[46] Karimi F, Erlandsson M, Lindhe Ö, and Långström B **Synthesis of 11C-labelled metomidate analogues as adrenocortical imaging agents** J Label Compd Radiopharm, 51 (2008), pp. 273-6.

[47] Wang T, Satoh F, Morimoto R, Nakamura Y, Sasano H, Auchus RJ, et al. **Gene expression profiles in aldosterone-producing adenomas and adjacent adrenal glands** Eur J Endocrinol, 164 (2011), pp. 613-9.
[48] Calvo R, Carlos R, and Erill S. *Etomidate and plasma esterase activity in man and experimental animals*. Pharmacology, 18 (1979), pp. 294-8.

[49] Lewi PJ, Heykants JJ, and Janssen PA. *Intravenous pharmacokinetic profile in rats of etomidate, a short-acting hypnotic drug*. Arch Int Pharmacodyn Ther, 220 (1976), pp. 72-85.

[50] Heykants JJ, Meuldermans WE, Michiels LJ, Lewi PJ, and Janssen PA. *Distribution, metabolism and excretion of etomidate, a short-acting hypnotic drug, in the rat. Comparative study of (R)-(+)-(−)-Etomidate*. Arch Int Pharmacodyn Ther, 216 (1975), pp. 113-29.